SPRY - NASDAQ
ARS Pharmaceuticals, Inc.
$9.07
+1.9%ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
At a Glance
Live Snapshotspry
Net Cash Provided by Financing Activities
Last Annual Value
104.60M
3-Year CAGR
-18%
5-Year CAGR
83%
10-Year CAGR
18%
ARS Pharmaceuticals, Inc. Competitors Analysis of Net Cash Provided by Financing Activities
| Company | Net Cash Provided by Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 ARS Pharmaceuticals, Inc. NASDAQ:SPRY | 104.60M | 147.5% | 14.5% | N/A | |
 Arbutus Biopharma Corporation NASDAQ:ABUS | 5.72M | -42.8% | -47.0% | -7.6% | |
 Savara Inc. NASDAQ:SVRA | 137.81M | 18.5% | 2.7% | 39.0% | |
 Kura Oncology, Inc. NASDAQ:KURA | 1.79M | -73.4% | N/A | -13.3% | |
 Palvella Therapeutics, Inc. NASDAQ:PVLA | -660.00K | N/A | N/A | N/A | |
 LENZ Therapeutics, Inc. NASDAQ:LENZ | 149.75M | 22.9% | -18.5% | N/A | |
 ProKidney Corp. NASDAQ:PROK | 25.57M | N/A | -18.6% | N/A | |
 Tyra Biosciences, Inc. NASDAQ:TYRA | 8.10M | 74.0% | -51.8% | N/A | |
 Rezolute, Inc. NASDAQ:RZLT | 107.33M | 110.1% | 15.8% | 25.9% |
ARS Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your SPRY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.